CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.
Charles River Laboratories (CRL) reported growth at the 2026 Global Healthcare Conference, with CEO Birgit Statham and CFO Glenn Sblendorio highlighting momentum in key segments. The company raised full-year organic growth and EPS guidance, citing stronger bookings in Discovery and Safety Assessment and improving margins in Manufacturing Support. Management also noted progress in stabilizing the non-human primate supply chain. However, they cautioned that recent strength may not sustain at the c
Evercore ISI Group maintained its 'Outperform' rating for Charles River Laboratories (CRL) and raised its price target from $300 to $320. The company's stock is currently trading at $279.37, which is 43.8% above its GF Value™ of $194.25, indicating potential overvaluation. CRL has a GF Score™ of 69/100, with strengths in profitability and momentum, but weaknesses in valuation. Insider selling totaled $42.6 million over the last three months.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CRL (CHARLES RIVER LABORATORIES INTERNATIONAL, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent CRL coverage spans earnings, financial news and market movers.
In the last 30 days, CRL insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($10.8M). The most active reporter was Andrews Nancy C with 1 filing. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
The new service reduces cell bank production time by 40%, likely boosting demand for CRL's lab services.
Guidance upgrade signals stronger near-term revenue and earnings growth, likely supporting the stock price.
The upgraded rating and higher target may attract buying interest and support short‑term price appreciation.
Quarterly results beat expectations on the margin side and signal a turnaround in DSA bookings.
Earnings beat offsets revenue decline, supporting upside.
AlphAI scores every news story that mentions CRL with an AI model for sentiment and relevance, and aggregates insider trades from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.
2 min readCharles River Laboratories (CRL) reported growth at the 2026 Global Healthcare Conference, with CEO Birgit Statham and CFO Glenn Sblendorio highlighting momentum in key segments. The company raised full-year organic growth and EPS guidance, citing stronger bookings in Discovery and Safety Assessment and improving margins in Manufacturing Support. Management also noted progress in stabilizing the non-human primate supply chain. However, they cautioned that recent strength may not sustain at the c
3 min readEvercore ISI Group maintained its 'Outperform' rating for Charles River Laboratories (CRL) and raised its price target from $300 to $320. The company's stock is currently trading at $279.37, which is 43.8% above its GF Value™ of $194.25, indicating potential overvaluation. CRL has a GF Score™ of 69/100, with strengths in profitability and momentum, but weaknesses in valuation. Insider selling totaled $42.6 million over the last three months.
2 min readCharles River Laboratories (CRL) is well-positioned for growth due to strong research-model demand and portfolio streamlining. The company's DSA segment shows improving demand, bookings, and backlog. CRL stock has surged 79% over the past year, outperforming its industry and the S&P 500. The company has a market cap of $13.92 billion and an earnings yield of 3.9%. However, mixed demand trends and NHP-related cost volatility remain risks. The Zacks Consensus Estimate for CRL’s 2026 earnings has i
3 min readAzenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
3 min readFOSTER JAMES C sold 33,561 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $300.00 ($10.07M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readCharles River Laboratories (CRL) partners with Medigen to support vaccine development, highlighting its role in complex biologics testing. The collaboration aligns with CRL's strategy to focus on high-value testing. Analysts project $4.1B revenue and $461.2M earnings by 2029, though some see slower growth due to potential industry shifts.
2 min readCharles River Laboratories (CRL) and Medigen Vaccine Biologics Corp. announced a collaboration to develop a multivalent enterovirus vaccine. The partnership leverages CRL's analytics for vaccine development and regulatory readiness, expanding CRL's biologics testing services and reducing reliance on animal testing. CRL, a $13.9B life sciences company, aims to diversify into higher-margin, data-driven analytics. Investors will watch for regulatory milestones and pipeline growth.
2 min readAurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.
2 min readCharles River Laboratories (CRL) CEO Birgit Girshick gifted 528 shares of common stock on 2026-08-19, leaving her with 35,485 direct and 43,803 indirect shares via a revocable trust. The gift was reported at $0.00 per share, with no Rule 10b5-1 trading plan involved.
1 min read
